Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
13/10/2026 11:25
BRIEF-Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045 Oct 13 (Reuters) - Cognition Therapeutics Inc CGTX.O:
COGNITION THERAPEUTICS ANNOUNCES ISSUANCE OF COMPOSITION OF MATTER PATENT, EXTENDING PROTECTION FOR ZERVIMESINE (CT1812) THROUGH 2045
COGNITION THERAPEUTICS - PATENT EXPIRES IN 2045; MAY BE EXTENDED UP TO FIVE YEARS UPON FDA APPROVAL
COGNITION THERAPEUTICS - FDA MEETING SCHEDULED NEXT WEEK FOR DLB PROGRAM; MANUFACTURING PLANNED Q1 2027
Source text: ID:nGNXblBCqz
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB